comparemela.com

Latest Breaking News On - E3 2022 - Page 1 : comparemela.com

Armata Pharmaceuticals Inc (ARMP) Reports Q3 2023 Financial Results and Corporate Updates

Continued Progress in Phage Therapeutics Development Amidst Increased Expenses

Deborah-birx
Armata-pharmaceuticals
Department-of-defense
Analysis-of-company-performance
Armata-pharmaceuticals-inc
Tailwind-phase
Balance-sheet
Cash-flows
Trmp
Administrative-expenses
Ash-and-cash-equivalents
Research-and-development

UroGen Pharma Ltd (URGN) Reports Growth in Q3 Revenue and Progress in Clinical Trials

Net Revenue Rises as Company Advances with UGN-102 Clinical Development

Liz-barrett
Clinical-development
Urogen-pharma-ltd
Income-statement
Elmyto
Product-revenue
Product-revenues
Progen
E3-2022
Research-and-development-expenses
Net-loss

Sanara MedTech Inc. Reports Record Sales in Q3 2023 with Narrowed Net Loss and Positive ...

Strategic Acquisitions and Product Launches Propel Growth Amidst Operational Challenges

District-of-columbia
United-states
Nasdaq
Sanara-medtech-inc
Sanara-medtech
New-product
Sanara-medtech-inc
Market-challenges
Sanara-medtech-inc
Net-loss
E3-2022

electroCore Inc (ECOR) Reports Substantial Sales Growth in Q3 2023

Net Sales Surge by 128% Year-Over-Year; Company Raises Full-Year Revenue Guidance

Core-inc
Department-of-defense
Department-of-veteran-affairs
Veteran-affairs
Investor-relations
Electrocore
Revenue-guidance
Financial-results
Net-loss
E3-2022

Fulcrum Therapeutics Inc (FULC) Reports Q3 2023 Financial Results and Business Highlights

Company's cash runway extended into 2026, with a net loss of $24.0 million for Q3 2023

Alexc-sapir
Fulcrum-therapeutics-inc
Iopharmaceutical-company
Sulc
Sickle-cell-disease
Cash-equivalents
Facioscapulohumeral-muscular-dystrophy
Fulcrum-therapeutics
E3-2022
Clinical-development
Cash-position

vimarsana © 2020. All Rights Reserved.